DY131 Chemical Properties

Melting point:

234-236 °C

Density 

1.11±0.1 g/cm3(Predicted)

storage temp. 

Sealed in dry,2-8°C

solubility 

DMSO: ≥14 mg/mL

form 

solid

pka

8.47±0.15(Predicted)

color 

yellow

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.

InChI

InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)

InChIKey

WLKOCYWYAWBGKY-UHFFFAOYSA-N

SMILES

C(NN=CC1=CC=C(N(CC)CC)C=C1)(=O)C1=CC=C(O)C=C1

Safety Information

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

2

MSDS

• Language:English Provider:SigmaAldrich

DY131 Usage And Synthesis

Description

DY131 (95167-41-2) is a selective agonist at estrogen-related receptors ERRβ and ERRγ with minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.1?Displays antiproliferative activity in prostate cancer cells.2?Promotes hormone production and cell fusion in cytotrophoblasts.3?In breast cancer cells DY131 arrests cells in G2/M and causes mitotic spindle defects.4?Inhibits osteoclastogenesis and protects against inflammatory bone loss induced by LPS?in vivo.5

Uses

DY131 is a selective estrogen-related receptors (ERRβ and ERRγ) agonist (1,2). It is also an antimitotic agent that inhibits breast cancer cell growth.

Definition

ChEBI: N-[[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide is a member of benzoic acids.

Biological Activity

Novel selective agonist at estrogen-related receptors ERR β and ERR γ . Displays minimal activity at ERR α , ER α and ER β at concentrations up to 30 μ M.

in vitro

dy131 was evaluated for its selectivity and efficacy in modulating the transcriptional activity of errα/β/γ and erβ/γ. cv-1 cells were transfected with reporter constructs or expression vectors and the fold activation of the reporter construct was determined at different concentrations of dy131. dy131 was found to be not able to activate the reporter construct or errα at any of the tested concentrations. in contrast, dy131 led to three- to fourfold activation of errβ at concentrations of 10-30 μm. activity on errγ was more pronounced with five-fold activation at 3 μm and maximal 6.6-fold activity observed at 30 μm. thus, dy131 was an selective errβ/γ ligand displaying preferential selectivity for errγ at lower concentrations [1].

storage

+4°C

References

[1] DONNA D. YU  Barry M F. Identification of an agonist ligand for estrogen-related receptors ERRβ/γ[J]. Bioorganic & Medicinal Chemistry Letters, 2005, 15 5: Pages 1311-1313. DOI:10.1016/j.bmcl.2005.01.025
[2] S YU. Orphan nuclear receptor estrogen-related receptor-β suppresses in vitro and in vivo growth of prostate cancer cells via p21WAF1/CIP1 induction and as a potential therapeutic target in prostate cancer[J]. Oncogene, 2007, 27 23: 3313-3328. DOI:10.1038/sj.onc.1210986
[3] DOROTHÉE POIDATZ. Trophoblast syncytialisation necessitates mitochondrial function through estrogen-related receptor-γ activation.[J]. Molecular human reproduction, 2015, 21 2: 206-216. DOI:10.1093/molehr/gau102
[4] MARY M HECKLER. Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.[J]. Oncotarget, 2016: 47201-47220. DOI:10.18632/oncotarget.9719
[5] HYUN-JU KIM. Estrogen-related receptor γ negatively regulates osteoclastogenesis and protects against inflammatory bone loss[J]. Journal of Cellular Physiology, 2018, 234 2: 1659-1670. DOI:10.1002/jcp.27035

DY131(95167-41-2)Related Product Information

• PF-01367338
• 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide
• Levetiracetam
• NORFLUOXETINE HYDROCHLORIDE
• DY131